Lenti-CD87 CAR (scFv-BBζ-IL12)-VP(VP-CAR-LC734)
The ready-to-use lentiviral particles of Lenti-CD87 CAR (scFv-BBζ-IL12)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv-41BB-CD3ζ-IL12 packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.
Type of Therapeutics
Chimeric Antigen Receptor
Small-cell lung cancer, Ovarian cancer
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.
PLAUR; plasminogen activator, urokinase receptor; CD87; UPAR; URKR; U-PAR
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.